文献速递外周动脉疾病

紫杉醇涂层球囊与普通球囊治疗股腘动脉支架内再狭窄的COPA CABANA试验

Paclitaxel-Coated Balloon vs Uncoated Balloon Angioplasty for Treatment of In-Stent Restenosis in the Superficial Femoral and Popliteal Arteries: The COPA CABANA Trial.
PubMed 文献 · J Endovasc Ther · 2020-02-25

COPA CABANA试验将88例股腘动脉支架内再狭窄患者随机分配至药物涂层球囊(DCB)组或普通球囊组,主要终点为6个月晚期管腔丢失(LLL)。DCB组6个月LLL显著低于普通球囊组,12个月靶病变血运重建(TLR)率也显著更低;对复发性再狭窄采用双倍剂量DCB治疗未出现可识别的不良事件。

要点

  • DCB治疗股腘动脉ISR的6个月LLL和12个月TLR均优于普通球囊。
  • 单剂量DCB组约2年时TLR记录达52%,需关注远期再狭窄。
  • 复发性ISR采用双倍剂量DCB治疗至24个月未需TLR,安全性可接受。

核心结论

  • DCB治疗股腘动脉ISR在6个月LLL和长达24个月的TLR方面显著优于普通球囊。
  • 对复发性ISR采用双倍剂量DCB治疗至24个月未引起可识别的不良事件或需TLR。

研究设计与样本

  • 研究者发起的、前瞻性、多中心、1:1随机研究,纳入88例股腘动脉ISR患者。
  • DCB组47例(平均年龄68.3±9.6岁,男性26例),普通球囊组41例(平均年龄67.6±10.2岁,男性26例)。
  • 另设观察性臂,纳入随机分组后≥30天出现复发性ISR的患者,采用双倍剂量DCB治疗。

主要发现

  • 6个月LLL在DCB组为0.34±1.12 mm,普通球囊组为1.58±1.10 mm(p<0.001)。
  • 12个月TLR在普通球囊组为37例中18例(49%),单剂量DCB组为43例中6例(14%,p=0.001),复发性ISR组无患者需TLR。
  • 单剂量DCB组在治疗后约2年时TLR记录为27例中14例(52%)。

关键数值与推荐

  • 主要终点为独立核心实验室评估的6个月血管造影晚期管腔丢失(LLL)。
  • 多数患者(66例,78%)为Rutherford 3级缺血;平均病变长度140 mm;31%(27例)为完全闭塞。

临床怎么用

  • 对于股腘动脉ISR,DCB可作为优于普通球囊的介入选择,以降低6个月LLL和12个月TLR。
  • 单剂量DCB治疗后仍需长期随访,因约2年时TLR率可达52%。
  • 复发性ISR可考虑重叠双倍剂量DCB治疗,但需更多证据确认远期安全性。

局限性

  • 样本量较小(88例随机),观察性臂病例数有限。
  • 单剂量DCB组约2年TLR率较高,提示需关注远期疗效。
  • 复发性ISR双倍剂量DCB治疗的安全性需更大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose: To investigate the efficacy and sustainability of drug-coated balloon (DCB) treatment of femoropopliteal in-stent restenosis (ISR). Materials and Methods: An investigator-initiated, prospective, multicenter, 1:1 randomized study enrolled 88 patients for treatment of ISR with DCB (n=47; mean age 68.3±9.6 years; 26 men) or uncoated balloon (n=41; mean age 67.6±10.2 years; 26 men) angioplasty (ClinicalTrials.gov identifier NCT01594684). Additionally, the protocol provided for an observational arm composed of patients from either randomized arm who experienced recurrent ISR ≥30 days after the index treatment. Redo treatment consisted of 2 DCBs sequentially inflated at the same location (double dose therapy). The majority of patients (66, 78%) had Rutherford category 3 ischemia. The mean lesion length was 140 mm; a third (27, 31%) were total occlusions. The primary endpoint was angiographic late lumen loss (LLL) at 6 months evaluated by an independent core laboratory. Results: Twenty-two patients (7 DCB +15 uncoated) were treated for recurrence with fully overlapping double DCB angioplasty. Six-month LLL was lower after DCB (0.34±1.12 mm) treatment than after angioplasty with an uncoated balloon (1.58±1.10 mm, p<0.001). At the 12-month follow-up, target lesion revascularization (TLR) was performed in 18 (49%) of 37 patients in the uncoated group, 6 (14%) of 43 patients in the single-dose DCB group (p=0.001), and no patients from the recurrent ISR group. At ~2 years after treatment, a remarkable number (14/27, 52%) of TLRs were recorded in the single-dose DCB group. Conclusion: Treatment with DCBs resulted in significantly less 6-month LLL and fewer TLRs up to 24 months than treatment with uncoated balloons. The double dose for treating recurrent ISR did not cause recognizable adverse events or require TLR up to 24 months.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Tepe G, Schroeder H, Albrecht T, et al. Paclitaxel-Coated Balloon vs Uncoated Balloon Angioplasty for Treatment of In-Stent Restenosis in the Superficial Femoral and Popliteal Arteries: The COPA CABANA Trial. J Endovasc Ther. 2020. PMID: 32096451. doi:10.1177/1526602820907917

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。